2,106 Shares in Zoetis Inc. (NYSE:ZTS) Purchased by Soltis Investment Advisors LLC

Soltis Investment Advisors LLC purchased a new stake in Zoetis Inc. (NYSE:ZTS) in the fourth quarter, Holdings Channel.com reports. The firm purchased 2,106 shares of the company’s stock, valued at approximately $343,000.

Other hedge funds have also recently bought and sold shares of the company. Darwin Wealth Management LLC acquired a new stake in shares of Zoetis during the third quarter worth approximately $31,000. First Personal Financial Services acquired a new stake in Zoetis in the third quarter valued at $33,000. Capital Performance Advisors LLP bought a new position in Zoetis during the 3rd quarter valued at $33,000. Dunhill Financial LLC increased its position in shares of Zoetis by 80.6% in the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock worth $33,000 after purchasing an additional 75 shares during the last quarter. Finally, Fortitude Family Office LLC raised its stake in shares of Zoetis by 1,387.5% in the 3rd quarter. Fortitude Family Office LLC now owns 238 shares of the company’s stock valued at $46,000 after purchasing an additional 222 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on ZTS shares. Morgan Stanley decreased their price target on Zoetis from $248.00 to $243.00 and set an “overweight” rating for the company in a research note on Wednesday, January 29th. Leerink Partnrs upgraded Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. Piper Sandler dropped their price objective on shares of Zoetis from $210.00 to $200.00 and set an “overweight” rating on the stock in a research note on Monday. Leerink Partners assumed coverage on Zoetis in a research report on Monday, December 2nd. They issued an “outperform” rating and a $215.00 target price on the stock. Finally, UBS Group initiated coverage on shares of Zoetis in a report on Monday, December 9th. They set a “neutral” rating and a $196.00 price target for the company. One research analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $214.00.

Insider Buying and Selling at Zoetis

In related news, EVP Roxanne Lagano sold 326 shares of the company’s stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total value of $55,804.68. Following the completion of the sale, the executive vice president now owns 16,107 shares in the company, valued at approximately $2,757,196.26. This represents a 1.98 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.16% of the stock is owned by corporate insiders.

Zoetis Price Performance

Shares of NYSE:ZTS opened at $174.47 on Wednesday. The stock’s 50 day moving average price is $169.16 and its 200 day moving average price is $179.15. Zoetis Inc. has a 12 month low of $144.80 and a 12 month high of $200.53. The stock has a market cap of $78.71 billion, a price-to-earnings ratio of 32.80, a PEG ratio of 2.77 and a beta of 0.90. The company has a debt-to-equity ratio of 1.26, a current ratio of 3.69 and a quick ratio of 2.27.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be issued a $0.50 dividend. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.15%. Zoetis’s payout ratio is currently 37.59%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.